One factor not mentioned with regard to a second drug is pricing.
A second drug will have similar development costs to amortize. By the time of its launch, a portion of our development costs will have been recovered, enabling Acadia to lower its price to protect its (100%) market share. This will make the economics or the second drug less attractive.
If a second drug is past the point of no return, then it will continue to seek approval, but there is now a significant disincentive for others (early on the development track) to suspend further work.
One factor not mentioned with regard to a second drug is...
-
- There are more pages in this discussion • 121 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.13 |
Change
0.020(0.15%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.44 | $13.07 | $5.021M | 378.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 11501 | $13.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.18 | 1539 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |